Highest-materiality recent filing
ProtoKinetix appoints new President, forms SightPath Biotech, patents valued at $253M
Director McDonough resigned March 31; June 17: Jones, Lamp, Brunt appointed directors, Brunt as President.
ProtoKinetix CEO updates on founder Clarence Smith's passing and AAGP molecule strategy
CEO Guzzetta acknowledges sudden passing of longtime leader Clarence Smith and commitment to his vision.
ProtoKinetix CEO Clarence Smith dies in accident; CFO Guzzetta named successor
President & CEO Clarence E. Smith died in a tragic accident on November 13, 2025.
ProtoKinetix CEO Clarence Smith dies in accident; CFO Guzzetta assumes all top roles
CEO Clarence E. Smith died Nov 13, 2025 in a tragic accident; served as CEO since 2015.
ProtoKinetix shareholders approve 20% increase in authorized common shares to 600M
Stockholders approved amendment raising authorized shares from 500M to 600M; 222,125,724 votes in favor.
ProtoKinetix issues 2M shares to CEO at $0.02/share in private placement raising $40K
Issued 2,000,000 shares to President/CEO Clarence E. Smith at $0.02 per share for total proceeds of $40,000.
ProtoKinetix issues 1.85M shares to CEO in private placement at $0.02/share
Issued 1,850,000 shares of common stock to President and CEO Clarence E. Smith.
ProtoKinetix issues 2.52M shares to CEO at $0.025; reprices 93.5M options to $0.028
Issued 2,520,000 shares to CEO Clarence Smith at $0.025/share in private placement, raising $63,000.
ProtoKinetix issues 1M units for $50k, grants 10M stock options to insiders and consultants
Private placement: 1M units (share + warrant at $0.05) to CEO Clarence Smith for $50,000.
Stockholders approve increase in authorized shares to 500M; re-elect directors Smith and McDonough
Increase in authorized shares from 400M to 500M approved (184,335,129 for, 1,583,019 against).
ProtoKinetix adopts amended bylaws updating stockholder meeting provisions
Board approved Amended and Restated Bylaws on December 20, 2021.
On March 31, 2026, Mr. Edward McDonough, after serving many years as a trusted advisor to ProtoKinetix, Incorporated (the “Company”) under the leadership of Clarence E. Smith, notified the Board of Directors of the Company (the “Board”) of his resignation from the Board effective immediately.
On June 17, 2026, Keith Brunt, a Translational Scientist and Associate Professor of Pharmacology, in the Faculty of Medicine at Dalhousie Medicine in New Brunswick, was appointed as a director and as the president of the Company, to hold such office until his successors are duly elected and qualified.
On June 17, 2026, Keith Brunt, a Translational Scientist and Associate Professor of Pharmacology, in the Faculty of Medicine at Dalhousie Medicine in New Brunswick, was appointed as a director and as the president of the Company, to hold such office until his successors are duly elected and qualified.
On June 17, 2026, Michael Jones, of Corbin, Kentucky, and Jason Lamp, of Roswell, Georgia were appointed as directors of the Company to serve as members of the Board, and to hold such office until their successors are duly elected and qualified.
On June 17, 2026, Michael Jones, of Corbin, Kentucky, and Jason Lamp, of Roswell, Georgia were appointed as directors of the Company to serve as members of the Board, and to hold such office until their successors are duly elected and qualified.
Max materiality 0.80 · Median 0.50 · Most common event other_material